Refine
Has Fulltext
- yes (22)
Is part of the Bibliography
- yes (22)
Year of publication
Document Type
- Doctoral Thesis (22) (remove)
Language
- English (22) (remove)
Keywords
- Maus (4)
- Raf <Biochemie> (4)
- Embryonalentwicklung (3)
- Signaltransduktion (3)
- Stammzelle (3)
- Apoptosis (2)
- Biochemie (2)
- C-RAF (2)
- Embryonale Stammzelle (2)
- Epigenetik (2)
Institute
- Institut für Medizinische Strahlenkunde und Zellforschung (22) (remove)
Imprinted genes play important roles in brain development. As the neural developmental capabilities of human parthenogenetic embryonic stem cells (hpESCs) with only a maternal genome were not assessed in great detail, hence here the potential of hpESCs to differentiate into various neural subtypes was determined. In addition DNA methylation and expression of imprinted genes upon neural differentiation was also investigated. The results demonstrated that hpESC-derived neural stem cells (hpNSCs) showed expression of NSC markers Sox1, Nestin, Pax6, and Musashi1 (MS1), the silencing of pluripotency genes (Oct4, Nanog) and the absence of activation of neural crest (Snai2, FoxD3) and mesodermal (Acta1) markers. Moreover, confocal images of hpNSC cultures exhibited ubiquitous expression of NSC markers Nestin, Sox1, Sox2 and Vimentin. Differentiating hpNSCs for 28 days generated neural subtypes with neural cell type-specific morphology and expression of neuronal and glial markers, including Tuj1, NeuN, Map2, GFAP, O4, Tau, Synapsin1 and GABA. hpNSCs also responded to region-specific differentiation signals and differentiated into regional phenotypes such as midbrain dopaminergic- and motoneuron-type cells. hpESC-derived neurons showed typical neuronal Na+/K+ currents in voltage clamp mode, elicited multiple action potentials with a maximum frequency of 30 Hz. Cell depicted a typical neuron-like current pattern that responded to selective pharmacological blockers of sodium (tetrodotoxin) and potassium (tetraethylammonium) channels. Furthermore, in hpESCs and hpNSCs the majority of CpGs of the differentially methylated regions (DMRs) KvDMR1 were methylated whereas DMR1 (H19/Igf2 locus) showed partial or complete absence of CpG methylation, which is consistent with a parthenogenetic (PG) origin. Upon differentiation parent-of-origin-specific gene expression was maintained in hpESCs and hpNSCs as demonstrated by imprinted gene expression analyses. Together this shows that despite the lack of a paternal genome, hpNSCs are proficient in differentiating into glial- and neuron-type cells, which exhibit electrical activity similar to newly formed neurons. Moreover, maternal-specific gene expression and imprinting-specific DNA-methylation are largely maintained upon neural differentiation. hpESCs are a means to generate histocompatible and disease allele-free ESCs. Additionally, hpESCs are a unique model to study the influence of imprinting on neurogenesis.
In mammals, the RAF family of serine/threonine kinases consists of three members, A-, B- and C-RAF. Activation of RAF kinases involves a complex series of phosphorylations. Although the most prominent phosphorylation sites of B- and C-RAF are well characterized, little is known about regulatory phosphorylation of A-RAF. Using mass spectrometry, we identified here a number of novel in vivo phosphorylation sites in A-RAF. The physiological role and the function of these sites were investigated subsequently by amino acid exchange at the relevant positions. In particular, we found that S432 participates in MEK binding and is indispensable for A-RAF signaling. On the other hand, phosphorylation within the activation segment does not contribute to epidermal growth factor-mediated activation. Regarding regulation of A-RAF activity by 14-3-3 proteins, we show that A-RAF activity is regulated differentially by its C-terminal and internal 14-3-3 binding domain. Furthermore, by use of SPR technique, we found that 14-3-3 proteins associate with RAF in an isoform-specific manner. Of importance, we identified a novel regulatory domain in A-RAF (referred to as IH-segment) positioned between amino acids 248 and 267, which contains seven putative phosphorylation sites. Three of these sites, serines 257, 262 and 264, regulate A-RAF activation in a stimulatory manner. The spatial model of the A-RAF fragment including residues between S246 and E277 revealed a “switch of charge” at the molecular surface of the IH-region upon phosphorylation, suggesting a mechanism in which the high accumulation of negative charges may lead to an electrostatic destabilization of protein/membrane interaction resulting in depletion of A-RAF from the plasma membrane. Activation of B- and C-RAF is regulated by phosphorylation at conserved residues within the negative-charge regulatory region (N-region). Identification of phosphopeptides covering the sequence of the N-region led to the conclusion that, similar to B- and C-RAF, kinase activity of A-RAF is regulated by phosphorylation of the N-region. Abrogation of A-RAF activity by S299A substitution and elevated activity of the A-RAF-Y301D-Y302D mutant confirmed this conclusion. In addition, we studied the role of the non-conserved residues within the N-region in the activation process of RAF kinases. The non-conserved amino acids in positions –3 and +1 relative to the highly conserved S299 in A-RAF and S338 in C-RAF have so far not been considered as regulatory residues. Here, we demonstrate that Y296R substitution in A-RAF led to a constitutively active kinase. In contrast, G300S substitution (mimicking B- and C-RAF) acts in an inhibitory manner. These data were confirmed by analogous mutations in C-RAF. Based on the three-dimensional structure of the catalytic domain of B-RAF, a tight interaction between the N-region residue S339 and the catalytic domain residue R398 was identified in C-RAF and proposed to inhibit the kinase activity of RAF proteins. Furthermore, Y296 in A-RAF favors a spatial orientation of the N-region segment, which enables a tighter contact to the catalytic domain, whereas a glutamine residue at this position in C-RAF abrogates this interaction. Considering this observation, we suggest that Y296, which is unique for A-RAF, is a major determinant of the low activating potency of this RAF isoform. Finally, the residues R359 in A-RAF and R398 in C-RAF, which interact with the N-region, are also involved in binding of phosphatidic acid. Substitution of this conserved arginine by alanine resulted in accumulation of hyper-phosphorylated form of RAF, suggesting that this residue play a crucial role in phosphorylation-mediated feedback regulation of A- and C-RAF. Collectively, we provide here for the first time a detailed analysis of in vivo A-RAF phosphorylation status and demonstrate that regulation of A-RAF by phosphorylation exhibits unique features compared with B- and C-RAF.
In neurons the Ras signaling pathway is activated by a large number of various stimuli, including trophic factors, neurotransmitters and modulatory peptides. Guanine nucleotide exchange factors (GEFs) mediate the activation of Ras GTPases, by catalyzing the exchange of GDP for GTP, and facilitate signaling networks crosstalk. In this work, very-KIND (VKIND), a new brain specific RasGEF was structurally and functionally characterized. VKIND belongs to the KIND protein family along with the non-receptor tyrosine phosphatases type 13 and Spir actin nucleation factors. The kinase non-catalytic C-lobe domain (KIND) is similar to the C-terminal protein kinase catalytic fold (C-lobe) of the p21-activated kinase (PAK). The open reading frame (ORF) of the VKIND gene of 5229 base pairs was cloned. The VKIND ORF translates into a protein of 1742 amino acids residues with a size of 191 kD. The VKIND protein structure is highly conserved among species and at present the protein is found only in Vertebratae and Echinodermatae. The arrangement of two KIND domains at its amino-terminal region, KIND1 and KIND2, is depicted in its name. The KIND module functions as a molecular interaction structure that is deprived of any enzymatic activity. While the precise occupation of the KIND1 domain remains elusive, the KIND2 domain binds to the microtubules-associated protein 2 (MAP2). The protein central portion features two clusters of high conservation of yet unknown function as well as a coiled-coil motif with a putative multiple protein-protein interaction activity. At the carboxy-terminal region VKIND features a guanine nucleotide exchange factor for Ras-like small GTPases (RasGEF) with a structural RasGEFN motif attached at its N-terminal site. The VKIND RasGEF motif is structurally related to the yeast catalytic domain CDC25. The closest relation of the VKIND RasGEF domain with an average sequence identity of 23% is assigned to the RasGEF domains of exchange factors specific for Rap GTPases with two unique insertions: the first one of 24 amino acids in the N-terminal end of the domain (between helixes αA and αB of the SOS1 RasGEF module) and the second one of 11 amino acids in the C-terminal part (between, helixes αJ and αK of the Sos1 RasGEF module). The RasGEFN domain plays a critical role in sustaining the structural and catalytical integrity of the guanidine exchange factor. VKIND is specifically and highly expressed in the murine nervous system during embryonic development and adulthood. During embryogenesis VKIND expression is present in the murine neural tube, telencephalon, retinal ganglion cells, and rhombencephalon. In the adult murine brain VKIND expression is most prominent in the cerebellum, however exclusively restricted to the granular and Purkinje cell layers. Subcellular distribution studies and time-lapse analysis revealed the gradual accumulation of VKIND into highly motile circular particles which featured estimated maximum velocity of 12 μm/min. By merging the nascent structures progressively grew to estimated 2 μm in size suggesting a role for VKIND in the vesicular transport process. Furthermore, the KIND1/KIND2 region of the VKIND protein was found to be phosphorylated by the p38 mitogen-activated protein kinase (MAPK), recently discovered to induce neurite outgrowth in response to hyperosmotic shock. In the light of VKIND negatively controlling neurite outgrowth, further elucidation of the complex Ras pathways may provide rewarding insights in the neuronal physiology.
Steps involved in the progression of non-small cell lung cancer (NSCLC) to metastasis are poorly understood. Expression of oncogenic C-RAF in lung epithelial cells has yielded a model for non-small cell lung cancer (NSCLC). The induced adenomas are characterised by high genomic stability, a lack of tumor progression and pronounced cell-cell contacts raising the question whether disruption of E-cadherin complexes would promote progression to metastasis. Two genetic approaches were used to evaluate the role of adherens junctions in a C-RAF driven mouse model for NSCLC: conditional ablation of the Cdh1 gene and expression of dominant negative (dn) E-cadherin. Disruption of E-cadherin function caused massive formation of intratumoral vessels that was reversible in the early phase of induction. Vascularized tumors grew more rapidly, developed invasive fronts and gave rise to micrometastasis. ß-catenin was identified as a critical effector of E-cadherin disruption leading to up-regulation of angiogenic inducers (VEGF-A and VEGF-C) in mouse and human lung tumor cell lines. In vivo, lung tumor cells with disrupted E-cadherin expressed ß-catenin target genes of endodermal and other lineages suggesting that reprogramming may be involved in metastatic progression.
Uniparental zygotes with two genomes from the same sex can be established from fertilised oocytes after pronuclear exchange. They contain two maternal (gynogenetic; GG) or paternal (androgenetic; AG) pronuclei and are not competent to develop into viable offspring but they can form blastocysts from which embryonic stem cells (ES cells) can be derived. The developmental potential of uniparental ES cells is not fully investigated. The restricted developmental potential of uniparental cells is cell-intrinsic and probably reflects the different roles maternal and paternal genomes play during development. Following blastocyst injection, both GG and AG ES cells show biased and parent-of-origin-specific chimaera formation. While the in vitro and in vivo neural differentiation potential of GG ES cells is well characterised the neural developmental potential of AG ES cells is less clear. In an earlier study the group of K. John McLaughlin reported that AG and GG ES cell-derived hematopoietic stem cells conveyed long-term, multi-lineage hematopoietic engraftment with no associated pathologies (Eckardt et al., 2007). The aim of this study was to investigate the potential of AG uniparental murine ES cells to differentiate in vitro and in vivo into neural progenitor / stem cells and further into neurons, astro- and oligodendroglia in comparison to GG and biparental (normal fertilised; N) ES cells. Uniparental and biparental ES cells were obtained from K. John McLaughlin’s group and a cell culture system was established to expand uniparental (AG, GG) and biparental N ES cells on murine embryonic fibroblasts (MEF). A multistep-protocol was used to differentiate ES cells towards pan-neural progenitor cells and neuronal and glial cell types (Brüstle et al., 1997). The ability of terminal neural differentiation in vitro was analysed by fluorescence microscopy using neuronal and glial lineage markers. In parallel, eGFP+ AG or N ES cells were injected into blastocysts prior to their transfer into foster mothers. At E12.5 and E14.5, embryos were isolated, forebrains were dissected and by means of fluorescence activated cell sorting (FACS) eGFP+ donor cells were isolated from chimeric brains. Both eGFP+ donor and corresponding eGFP- blastocyst-derived brain cells were expanded and analyses of differentiation potential and self-renewal capacity were performed. Also, cryosections of E12.5 chimeric brains were analysed for donor contribution to the neuronal lineage by immunofluorescence microscopy. Here it is described that following in vitro differentiation, AG pan-neural progenitor cells have similar abilities to differentiate into neuronal and glial lineages as GG and N pan-neural progenitor cells. In cryosections of E12.5 chimeric brains no differences in brain engraftment and formation of immature neuronal cells between uniparental AG and N donor cells were detected. AG and N ES cell-derived cells isolated from chimeric foetal brains by FACS exhibited similar neurosphere initiating cell frequencies and neural multi-lineage differentiation potential. Therefore, the data of this study suggest that the previously described differences in the in vivo engraftment pattern of uniparental inner cell mass (ICM) cells in foetal brains (Keverne et al., 1996) are not primarily due to limitations in the proliferation or differentiation properties of uniparental neural progenitor cells. The results presented here indicate that AG ES cell-derived neural progenitor / stem cells did not differ from N neural progenitor / stem cells in their self-renewal and their neural multi-lineage differentiation potential. Also AG ES cell-derived cells contributed to developing brains at early foetal developmental stages showing a widespread and balanced distribution in chimeric brains. AG brain cells form neurospheres with self-renewal and neural differentiation capacity similar to N ES cell-derived brain cells. Thus, the data of this study together indicate that the neural developmental potential in vivo and in vitro of AG and N ES cells does not differ.
Members of the RAF protein kinase family are key regulators of diverse cellular processes. The need for isoform-specific regulation is reflected by the fact that all RAFs not only display a different degree of activity but also perform isoform-specific functions at diverse cellular compartments. Protein-protein-interactions and phosphorylation events are essential for the signal propagation along the Ras-RAF-MEK-ERK cascade. More than 40 interaction partners of RAF kinases have been described so far. Two of the most important regulators of RAF activity, namely Ras and 14-3-3 proteins, are subject of this work. So far, coupling of RAF with its upstream modulator protein Ras has only been investigated using truncated versions of RAF and regardless of the lipidation status of Ras. We quantitatively analyzed the binding properties of full-length B- and C-RAF to farnesylated H-Ras in presence and absence of membrane lipids. While the isolated Ras-binding domain of RAF exhibit a high binding affinity to both, farnesylated and nonfarnesylated H-Ras, the full-length RAF kinases demonstrate crucial differences in their affinity to Ras. In contrast to C-RAF that requires carboxyterminal farnesylated H-Ras for interaction at the plasma membrane, B-RAF also binds to nonfarnesylated H-Ras in the cytosol. For identification of the potential farnesyl binding site we used several fragments of the regulatory domain of C-RAF and found that the binding of farnesylated H-Ras is considerably increased in the presence of the cysteine-rich domain of RAF. In B-RAF a sequence of 98 amino acids at the extreme N terminus enables binding of Ras independent of its farnesylation status. The deletion of this region altered Ras binding as well as kinase properties of B-RAF to resemble C-RAF. Immunofluorescence studies in mammalian cells revealed essential differences between B- and C-RAF regarding the colocalization with Ras. In conclusion, our data suggest that that B-RAF, in contrast to C-RAF, is also accessible for nonfarnesylated Ras in the cytosolic environment due to its prolonged N terminus. Therefore, the activation of B-RAF may take place both at the plasma membrane and in the cytosolic environment. Furthermore, the interaction of RAF isoforms with Ras at different subcellular sites may also be governed by the complex formation with 14-3-3 proteins. 14-3-3 adapter proteins play a crucial role in the activation of RAF kinases, but so far no information about the selectivity of the seven mammalian isoforms concerning RAF association and activation is available. We analyzed the composition of in vivo RAF/14-3-3 complexes isolated from mammalian cells with mass spectrometry and found that B-RAF associates with a greater variety of 14-3-3 proteins than C- and A-RAF. In vitro binding assays with purified proteins supported this observation since B-RAF showed highest affinity to all seven 14-3-3 isoforms, whereas C-RAF exhibited reduced affinity to some and A-RAF did not bind to the 14-3-3 isoforms epsilon, sigma, and tau. To further examine this isoform specificity we addressed the question of whether both homo- and heterodimeric forms of 14-3-3 proteins participate in RAF signaling. By deleting one of the two 14-3-3 isoforms in Saccharomyces cerevisiae we were able to show that homodimeric 14-3-3 proteins are sufficient for functional activation of B- and C-RAF. In this context, the diverging effect of the internal, inhibiting and the activating C-terminal 14-3-3 binding domain in RAF could be demonstrated. Furthermore, we unveil that prohibitin stimulates C-RAF activity by interfering with 14-3-3 at the internal binding site. This region of C-RAF is also target of phosphorylation as part of a negative feedback loop. Using tandem MS we were able to identify so far unknown phosphorylation sites at serines 296 and 301. Phosphorylation of these sites in vivo, mediated by activated ERK, leads to inhibition of C-RAF kinase activity. The relationship of prohibitin interference with 14-3-3 binding and phosphorylation of adjacent sites has to be further elucidated. Taken together, our results provide important new information on the isoform-specific regulation of RAF kinases by differential interaction with Ras and 14-3-3 proteins and shed more light on the complex mechanism of RAF kinase activation.
The proteins of the RAF family (A-RAF, B-RAF, and C-RAF) are serine/threonine-kinases that play important roles in development, mature cell regulation and cancer. Although it is widely held that their localization on membranes is an important aspect of their function, there are few data addressing this aspect of their mode of action. Here, we report that each member of the RAF family exhibits a specific distribution at the level of cellular membranes, and that C-RAF is the only isoform that directly targets mitochondria. We find that the RAF kinases exhibit intrinsic differences in terms of mitochondrial affinity, and that C-RAF is the only isoform that binds this organelle efficiently. This affinity is conferred by the C-RAF amino-terminal domain, and does not depend on the presence of RAS GTPases on the surface of mitochondria. Furthermore, we analyze the consequences of C-RAF activation on the cellular and molecular level. C-RAF activation on mitochondria dramatically changes their morphology and their subcellular distribution. On the molecular level, we examine the role of C-RAF in the regulation of the pro-apoptotic Bcl-2 family member BAD. This protein exhibits the original mode of regulation by phosphorylation. Although several reports addressed the regulation of BAD by C-RAF, the exact mode of action as well as the consequences of C-RAF activation on BAD are still not completely understood. We show that the inducible activation of C-RAF promotes the rapid phosphorylation of BAD on Serine-112 (Ser-75 in the human protein), through a cascade involving the kinases MEK and RSK. Our findings reveal a new aspect of the regulation of BAD protein and its control by the RAF pathway: we find that C-RAF activation promotes BAD poly-ubiquitylation in a phosphorylation-dependent fashion, and increases the turn-over of this protein through proteasomal degradation.
In neoplastic diseases the tumor stroma and especially tumor-associated macrophages (TAMs) play an important role in tumor growth and progression. TAMs exhibit an intensive cross-talk with tumor cells resulting in the promotion of angiogenesis and the inhibition of local protective immune responses in certain tumor entities. Therefore, TAMs are a potential target for tumor therapy. Here it was shown that intravenously applied intracellular bacteria like Salmonella and Shigella primarily target TAMs. To exploit this feature a growth attenuated Shigella strain with the capacity to induce apoptosis in macrophages was designed. Shigella are invasive bacteria that penetrate the colonic tissue and initiate an acute inflammation. In macrophages, Shigella rapidly induces caspase-1 processing and apoptosis via the virulence factor IpaB. By genomic deletion of the aroA-locus a metabolically attenuated strain defective in intracellular growth but with retained capacity of infection, cell-to-cell spread, caspase-1 processing and apoptosis induction in macrophages was designed. It was shown that this strain primarily targets TAMs in 4T1 cell induced and transgenic MMTV-HER2/new breast cancer models. Shigella were almost exclusively found intracellularly, whereas growth attenuated Salmonella were also found extracellularly at late time points. The metabollically attenuated Shigella strain with retained virulence, but not avirulent Shigella strains, was able to activate caspase-1 and induce apoptosis in TAMs at all time points (4 h, 6 h and 7 d p.i.) in both breast cancer models. This unrestricted apoptosis induction translated into a substantial, long-lasting and highly significant reduction of TAMs number (up to 70 %) in both models. In contrast, Salmonella could only induce apoptosis in TAMs at early time points (6 h p.i.) and failed to reduce TAMs in both models. In the 4T1 model, the effect on tumor size was monitored and treatment of the mice with the attenuated Shigella strain resulted in a complete block of tumor growth. Finally, Shigella primarily infected the macrophage fraction, activated caspase-1 and induced apoptosis in cells derived from a human ovarian carcinoma ex vivo. Taken together, this data suggests that growth attenuated intracellular bacteria capable of inducing apoptosis in TAMs are a promising therapeutic option for certain cancer diseases where TAMs have a proven role for tumor growth or progression.
Development of novel Listeria monocytogenes strains as therapeutic agents for targeted tumor therapy
(2010)
Despite marked progress in development and improvement of cancer therapies the rate of cancer related death remained stable over the last years. Especially in treating metastases alternative approaches supporting current therapies are required. Bacterial and viral vectors have been advanced from crude tools into highly sophisticated therapeutic agents detecting and treating neoplastic leasions. They might be potent enough to fill in this therapeutic demand. In this thesis Listeria monocytogenes was investigated as carrier for targeted bacterial cancer therapy. One part of the study focussed on modification of a functional bacterial mRNA delivery system. Genomic integration of T7 RNA polymerase driving mRNA production allowed reduction to an one-plasmid-system and thereby partially relieved the growth retardation exerted by mRNA delivery. Importantly the integration allowed metabolic attenuation of the mRNA delivery mutant potentially enabling in vivo applications. Further expansion of the bacterial RNA delivery system for transfer of shRNAs was examined. Bacterial mutants producing high amounts of RNA containing shRNA sequences were constructed, however a functional proof of gene silencing on delivery in eukaryotic cell lines was not achieved. The second part of this thesis focussed on increasing tumor colonization by Listeria monocytogenes in vivo. Coating bacteria with antibodies against receptors overexpressed on distinct tumor cell lines enabled specific bacterial internalization into these cells in vitro. Optimization of the bacterial antibody coating process resulted in an up to 104-fold increase of intracellular bacteria. Combination of this antibody-mediated targeting with the delivery of prodrug-converting enzymes showed a cytotoxic effect in cell lines treated with the corresponding prodrug. Since incubation in murine serum completely abrogated antibodymediated bacterial internalization the antibodies were covalently linked to the bacteria for application in xenografted tumor mice. Bacteria coated and crosslinked in this manner showed enhanced tumor targeting in a murine tumor model demonstrating antibodymediated bacterial tumor targeting in vivo. Independent of antibody-mediated tumor targeting the intrinsic tumor colonization of different Listeria monocytogenes mutants was examined. Listeria monocytogenes ΔaroA ΔinlGHE colonized murine melanoma xenografts highly efficient, reaching up to 108 CFU per gram of tumor mass 7 days post infection. Taken together the presented data shows highly promising aspects for potential bacterial application in future tumor therapies. Combination of the delivery systems with antibodymediated- and intrinsic bacterial tumor targeting might open novel dimensions utilizing Listeria monocytogenes as therapeutic vector in targeted tumor therapy.